AstraZeneca in deal with Kangtai Bio to supply potential COVID-19 vaccine in China

AstraZeneca in deal with Kangtai Bio to supply potential COVID-19 vaccine in China

FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the
File photo of the company logo for pharmaceutical company AstraZeneca. (Photo: REUTERS/Brendan McDermid)

BEIJING: AstraZeneca has signed an exclusive framework agreement with China's Shenzhen Kangtai Biological Products to supply its COVID-19 vaccine candidate in mainland China, the British pharmaceutical giant said on Thursday (Aug 6).

To meet market demand in China, Shenzhen Kangtai is obliged to make sure it has an annual production capacity of at least 100 million doses of the experimental shot AZD1222 – which AstraZeneca co-developed with researchers at Oxford University – by the end of this year, and a capacity of at least 200 million doses by the end of next year, AstraZeneca said in a statement on the Chinese social media site WeChat.

The two companies will also explore the possiblity of cooperation on the vaccine candidate in other markets, AstraZeneca said.

BOOKMARK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak: https://cna.asia/telegram

Source: Reuters/dv

Bookmark